KVUE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.70B

+1.17%

0.228

-12.48%

3.87B

+3.39%

0.258

+7.7%

3.95B

+2.96%

0.303

+4.63%

Estimates Revision

The market is revising Downward the revenue expectations for Kenvue Inc. (KVUE) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by 1.08%.

Revenue Estimates for FY2025

Revise Downward

-0.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.33%

In Past 3 Month

Stock Price

Go Up

+1.08%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 19.42 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

9 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

17.00

Averages

19.42

High

23.00

Current: 0.000

Low

17.00

Averages

19.42

High

23.00

Argus

John Staszak

Hold

Buy

upgrade

$120

2025-11-13

Reason

Argus

John Staszak

Price Target

$120

2025-11-13

upgrade

Hold

Buy

Reason

As previously reported, Argus analyst John Staszak upgraded Kimberly-Clark (KMB) to Buy from Hold with a $120 price target. The firm notes that the stock has underperformed recently, but the company has delivered a Q3 earnings beat and also announced the acquisition of Kenvue (KVUE) that is expected to close in the second half of next year, the analyst tells investors in a research note.

Barclays

Equal Weight

maintain

$17 -> $18

2025-11-10

Reason

Barclays

Price Target

$17 -> $18

2025-11-10

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Kenvue to $18 from $17 and keeps an Equal Weight rating on the shares following the Q3 report. The company's sales came in below expectations, with low incidence levels and continued destocking, the analyst tells investors in a research note. However, the firm sees "some green shoots" in Kenvue's Skin Health and Beauty segment.

Morgan Stanley

Equal Weight

downgrade

$144 -> $125

2025-11-04

Reason

Morgan Stanley

Price Target

$144 -> $125

2025-11-04

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Kimberly-Clark (KMB) to $125 from $144 and keeps an Equal Weight rating on the shares after the company announced an agreement to acquire Kenvue (KVUE). The firm understands the pullback in shares given a large degree of execution risk with the deal and uncertainty on Kenvue's portfolio, and the analyst is lowering the firm's target to reflect higher risk from the deal and execution uncertainty, though it sees "the glass as more half full" on Kimberly-Clark's stock after the pullback, the analyst tells investors.

Wells Fargo

Equal Weight

downgrade

$129 -> $110

2025-11-04

Reason

Wells Fargo

Price Target

$129 -> $110

2025-11-04

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Kimberly-Clark to (KMB) $110 from $129 and keeps an Equal Weight rating on the shares. The firm notes the company intends to acquire Kenvue (KVUE) in a stock and cash deal valued at $48.7B. Kimberly-Clark's stock reaction was historically negative, reflecting a material change in the investment case, risks associated with Kenvue, and needed execution on big synergy targets.

Canaccord

Buy

Hold

downgrade

$26 -> $15

2025-10-29

Reason

Canaccord

Price Target

$26 -> $15

2025-10-29

downgrade

Buy

Hold

Reason

Canaccord downgraded Kenvue to Hold from Buy with a price target of $15, down from $26.

Canaccord

Buy

Hold

downgrade

$26 -> $15

2025-10-29

Reason

Canaccord

Price Target

$26 -> $15

2025-10-29

downgrade

Buy

Hold

Reason

As previously reported, Canaccord downgraded Kenvue to Hold from Buy with a price target of $15, down from $26. With the HHS looking to link acetaminophen use in pregnancy to autism, Texas suing the company for deceptive marketing and lawsuits in the UK bringing talc liability to the table, the firm believes continued negative headlines and legal issues hamper the company's turnaround and also likely hamper any potential sale of all or part of the company. Finding itself in the news, for reasons "it can't generally control," will likely keep a lid on valuation, the analyst argues.

Valuation Metrics

The current forward P/E ratio for Kenvue Inc (KVUE.N) is 15.99, compared to its 5-year average forward P/E of 18.14. For a more detailed relative valuation and DCF analysis to assess Kenvue Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.14

Current PE

15.99

Overvalued PE

20.24

Undervalued PE

16.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.81

Current EV/EBITDA

11.72

Overvalued EV/EBITDA

13.89

Undervalued EV/EBITDA

11.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.57

Current PS

2.16

Overvalued PS

2.89

Undervalued PS

2.26

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KVUE News & Events

Events Timeline

No data

News

7.0

01-08PRnewswire

Halper Sadeh Investigates Potential Securities Violations for Multiple Companies

7.5

01-08Fool

Shopify Reaches $217 Billion Market Cap, Strong Market Performance

7.5

01-08NASDAQ.COM

Shopify Reaches $217 Billion Market Cap, Boosting E-commerce Growth

People Also Watch

Frequently Asked Questions

What is Kenvue Inc (KVUE) stock price today?

The current price of KVUE is 16.83 USD — it has decreased -0.94 % in the last trading day.

What is Kenvue Inc (KVUE)'s business?

Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

What is the price predicton of KVUE Stock?

What is Kenvue Inc (KVUE)'s revenue for the last quarter?

Kenvue Inc revenue for the last quarter amounts to 3.76B USD, decreased -3.46 % YoY.

What is Kenvue Inc (KVUE)'s earnings per share (EPS) for the last quarter?

Kenvue Inc. EPS for the last quarter amounts to 0.21 USD, increased 5.00 % YoY.

What changes have occurred in the market's expectations for Kenvue Inc (KVUE)'s fundamentals?

How many employees does Kenvue Inc (KVUE). have?

Kenvue Inc (KVUE) has 22000 emplpoyees as of January 10 2026.

What is Kenvue Inc (KVUE) market cap?

Today KVUE has the market capitalization of 32.24B USD.